Integra LifeSciences (NASDAQ:IART) Releases FY25 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $2.41 to $2.51 for the period, compared to the consensus EPS estimate of $2.53. The company issued revenue guidance of $1.650 billion to $1.715 billion, compared to the consensus revenue estimate of $1.71 billion. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IART shares. Citigroup increased their price objective on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Integra LifeSciences has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Trading Up 14.1 %

NASDAQ IART traded up $3.12 during trading hours on Tuesday, hitting $25.17. 473,108 shares of the company were exchanged, compared to its average volume of 558,733. The stock has a market cap of $1.94 billion, a PE ratio of -277.74, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. The stock has a 50-day moving average price of $23.68 and a 200 day moving average price of $21.81. Integra LifeSciences has a 52 week low of $16.81 and a 52 week high of $44.91. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.86 by $0.11. The company had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. Integra LifeSciences’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.89 EPS. Analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Michael J. Mcbreen sold 1,700 shares of Integra LifeSciences stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total transaction of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. The trade was a 2.94 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.10% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.